To evaluate the clinical translational potential of TP5 as an immunotherapeutic adjuvant in cancer therapy, we assessed its capacity to improve adoptive T cell transfer efficacy using an established B16-OVA melanoma model. The gene discussed is TMPO; the disease is cancer.